Alzheimer’s Disease

Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR®

February 21, 2018

Amneal Pharmaceuticals has launched memantine hydrochloride extended-release capsules, the company’s AB-rated equivalent for Namenda XR®, in 7 mg, 14 mg, 21 mg and 28 mg strengths. The product is manufactured here in the United States in the company’s recently expanded Brookhaven, New York facility. Annual U.S. sales of Namenda XR® were $929 million, according to […]

Latest Alzheimer’s Flop Raises Doubts About ‘Amyloid Hypothesis’

January 25, 2018

Even after Eli Lilly announced that its experimental Alzheimer’s drug solanezumab had failed in clinical trials in late 2016, it continued investigating its potential in patients at the very earliest stages of the memory-stealing disease. The hope was that if the drug could eliminate soluble amyloid-beta—the protein blamed for the brain plaques that form in […]

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies

January 4, 2018

TORONTO and CAMBRIDGE, MA, Jan. 4, 2018 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer’s disease (AD), PMN310, showed absence of binding to amyloid beta (Aβ) plaque in and around blood vessels in AD […]

Comprehend Systems Appoints New CEO in Response to Surging Demand for Clinical Intelligence Solutions; Enterprise Growth Expert to Scale Company and Expand Partner Ecosystem

November 20, 2017

Redwood City, Calif., November 13, 2017—Comprehend Systems, Inc., the leader in Clinical Intelligence solutions, has named Terry Cunningham CEO.  Cunningham will focus on scaling Comprehend in response to explosive customer demand for solutions that reduce time and risk in clinical trials. Cunningham will also drive expanded partner programs to help sponsors achieve faster, better clinical […]

Bioclinica Acquires MDDX Research & Informatics Combining Advanced Image Management Cloud Technology with Its Scientific and Medical Imaging Leadership

November 7, 2017

Best-in-class solution ensures sponsors and CROs have global access to efficient, accurate, and scalable medical imaging to drive better data and outcomes DOYLESTOWN, Pa., Nov. 6, 2017 – Bioclinica®, the world-leading provider of scientific-enabled Medical Imaging, eHealth, and patient-centric solutions supporting clinical research, today announces it has acquired Silicon Valley-based MDDX Research & Informatics, adding […]

Abbvie, Alector To Develop Novel Treatments For Alzheimer’s Disease

October 26, 2017

AbbVie has collaborated with Alector to develop and commercialize new treatments for Alzheimer’s disease and other neurodegenerative disorders.   Under the deal, the companies will study a portfolio of antibody targets, of which AbbVie will have global development and commercial rights to two targets.   Alector has developed an advanced immuno-neurology technology platform to simultaneously […]

The Alzheimer’s Drug Discovery Foundation and Science Exchange Launch ADDF ACCESS to Advance CNS Research New “CRO Finder” Connects Scientists with Specialized Resources

June 14, 2017

The Alzheimer’s Drug Discovery Foundation and Science Exchange Launch ADDF ACCESS to Advance CNS Research New “CRO Finder” Connects Scientists with Specialized Resources NEW YORK, NY, June 7, 2017– The Alzheimer’s Drug Discovery Foundation (ADDF), the only public charity solely focused on funding the development of drugs for Alzheimer’s, and Science Exchange today announced the […]

Certara Launches CODEx to Inform Comparative Effectiveness and Drug Development Decisions

June 6, 2017

CODEx streamlines the analysis of therapeutic area-specific literature data to assess a new drug candidate’s likelihood of regulatory and commercial success Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today launched its Clinical Outcomes Database Explorer (CODEx). An intuitive, web-based platform, CODEx enables drug […]

Worldwide Clinical Trials Expert to Present on Patient Engagement at DIA 2017

June 1, 2017

Barbara Zupancic, MBA, MSc, to discuss best practices for developing and implementing a patient-centered approach to effectively engage subjects in varying stages of Alzheimer’s Disease. MORRISVILLE, NC, June 1, 2017 – Barbara Zupancic, MBA, MSc, Director, Global Patient Recruitment and Retention at Worldwide Clinical Trials (, will present at one of the life sciences industry’s […]

The Global Alzheimer’s Crisis: New Paradigms in Clinical Trials and Longitudinal Screening

May 2, 2017

There is scientific knowledge. And there is public perception. And often, the two collide. Nowhere is this reality more explicit than with the current state of Alzheimer’s disease research. Without a definitive cause or diagnosis – and no cure in sight – many adults see no reason to assess their risk, or determine their cognitive […]

23andMe — finally— gets nod to test for risk of Alzheimer’s, Parkinson’s, other diseases

April 13, 2017

More than three years after federal regulators stripped it from marketing its “spit kits” as a way to probe for the genetic likelihood of getting Alzheimer’s, Parkinson’s or a host of other diseases, 23andMe Inc. won Food and Drug Administration approval Thursday for its tests. The decision is huge for the Mountain View company, which […]

Big Developments in Alzheimer’s Research

November 2, 2012

Promising New Advances in Alzheimer’s Disease Treatment Alzheimer’s Disease is one of the most costly diseases to our society, and one of the most difficult to understand and treat. There is no cure for AD, but there is hope for the future. It is believed that this degenerative disease may be slowed if detected early […]